(NASDAQ: BRTX) Biorestorative Therapies's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 12.96%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 17.59%.
Biorestorative Therapies's earnings in 2025 is -$8,979,381.On average, 1 Wall Street analyst forecast BRTX's earnings for 2025 to be -$8,105,162, with the lowest BRTX earnings forecast at -$8,105,162, and the highest BRTX earnings forecast at -$8,105,162. On average, 1 Wall Street analyst forecast BRTX's earnings for 2026 to be -$6,304,015, with the lowest BRTX earnings forecast at -$6,304,015, and the highest BRTX earnings forecast at -$6,304,015.
In 2027, BRTX is forecast to generate $21,913,958 in earnings, with the lowest earnings forecast at $21,913,958 and the highest earnings forecast at $21,913,958.